Form 4: Lineage Cell Therapeutics CFO Jill Howe Acquires 15,000 Shares

Lineage Cell Therapeutics' Chief Financial Officer, Jill Howe, purchased 15,000 shares of the company's common stock at an average price of $0.59 per share.

Summary

• Jill Howe, the Chief Financial Officer of Lineage Cell Therapeutics, Inc., acquired 15,000 common shares on November 26, 2024.
• The shares were purchased at a weighted average price of $0.59, with individual transaction prices ranging from $0.5925 to $0.5929.
• Following the transaction, Ms. Howe directly owns 25,500 shares of Lineage Cell Therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the purchase of shares by the CFO is a positive sign, it's a routine transaction and doesn't indicate a major shift in the company's outlook.

Positives

• The CFO's purchase of shares could be seen as a positive signal of confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, which is common for corporate insiders when they buy or sell shares of their company. It provides transparency into insider transactions.

Comparison to Industry Standards

• Insider trading activity is a common occurrence in publicly traded companies, and this transaction is consistent with standard practices.
• Form 4 filings are a routine part of regulatory compliance for company officers and directors.

Stakeholder Impact

• The share purchase by the CFO may have a minor positive impact on shareholder confidence.

Key Dates

Keywords

Lineage Cell Therapeutics, LCTX, Jill Howe, insider trading, share purchase, CFO, common stock